siRNA for gene silencing: a route to drug target discovery
- PMID: 15351359
- DOI: 10.1016/j.coph.2004.06.003
siRNA for gene silencing: a route to drug target discovery
Abstract
The identification of RNA interference in mammalian cells, mediated via both virally-derived short interference RNA (siRNA) and endogenously produced microRNA, has revolutionised our understanding of the translational control of gene expression. Indeed, since its initial discovery, siRNA has been rapidly deployed for the elucidation of gene function and the identification of potential drug targets, a process often known as target discovery. In this review, we briefly discuss the mechanism of RNA interference and then critically examine the use of siRNA in target discovery, with a particular emphasis upon issues such as efficacy, selectivity, delivery and application in high-throughput studies.
Similar articles
-
RNA interference as a novel and powerful tool in immunopharmacological research.Int Immunopharmacol. 2007 Apr;7(4):417-26. doi: 10.1016/j.intimp.2006.12.011. Epub 2007 Jan 22. Int Immunopharmacol. 2007. PMID: 17321464 Review.
-
Toxicogenomics of non-viral drug delivery systems for RNAi: potential impact on siRNA-mediated gene silencing activity and specificity.Adv Drug Deliv Rev. 2007 Mar 30;59(2-3):164-82. doi: 10.1016/j.addr.2007.03.010. Epub 2007 Mar 21. Adv Drug Deliv Rev. 2007. PMID: 17481774 Review.
-
Barriers to successful delivery of short interfering RNA after systemic administration.Clin Exp Pharmacol Physiol. 2008 Nov;35(11):1371-6. doi: 10.1111/j.1440-1681.2008.04992.x. Epub 2008 Jun 18. Clin Exp Pharmacol Physiol. 2008. PMID: 18565190 Review.
-
RNA interference for the identification of disease-associated genes.Curr Opin Mol Ther. 2004 Apr;6(2):136-40. Curr Opin Mol Ther. 2004. PMID: 15195924 Review.
-
Nonviral vector-mediated RNA interference: its gene silencing characteristics and important factors to achieve RNAi-based gene therapy.Adv Drug Deliv Rev. 2009 Jul 25;61(9):760-6. doi: 10.1016/j.addr.2009.04.006. Epub 2009 Apr 20. Adv Drug Deliv Rev. 2009. PMID: 19386274 Review.
Cited by
-
Intracellular Delivery of siRNA by Polycationic Superparamagnetic Nanoparticles.J Drug Deliv. 2012;2012:218940. doi: 10.1155/2012/218940. Epub 2012 Aug 30. J Drug Deliv. 2012. PMID: 22970377 Free PMC article.
-
Construction and Biological Evaluation of a Novel Integrin ανβ₃-Specific Carrier for Targeted siRNA Delivery In Vitro.Molecules. 2017 Feb 4;22(2):231. doi: 10.3390/molecules22020231. Molecules. 2017. PMID: 28165399 Free PMC article.
-
MALDI-TOF mass spectral analysis of siRNA degradation in serum confirms an RNAse A-like activity.Mol Biosyst. 2007 Jan;3(1):43-50. doi: 10.1039/b611612d. Epub 2006 Nov 20. Mol Biosyst. 2007. PMID: 17216055 Free PMC article.
-
Device-based local delivery of siRNA against mammalian target of rapamycin (mTOR) in a murine subcutaneous implant model to inhibit fibrous encapsulation.J Control Release. 2010 Nov 1;147(3):400-7. doi: 10.1016/j.jconrel.2010.08.019. Epub 2010 Aug 19. J Control Release. 2010. PMID: 20727922 Free PMC article.
-
Lung delivery studies using siRNA conjugated to TAT(48-60) and penetratin reveal peptide induced reduction in gene expression and induction of innate immunity.Bioconjug Chem. 2007 Sep-Oct;18(5):1450-9. doi: 10.1021/bc070077d. Epub 2007 Aug 21. Bioconjug Chem. 2007. PMID: 17711319 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources